Based on existing evidence, there may be great differences in tumor biology between patients with NSCLC harboring TP53 mutations and those without TP53 mutations, and the mutation profiling of metastatic lesions may differ from that of primary lesions (38–43). The gene discussed is TP53; the disease is non-small cell lung carcinoma.